Medical Xpress July 29, 2024

The World Health Organization announced Monday a new project to accelerate the development in poorer countries of vaccines for human bird flu infections using cutting-edge messenger RNA technology.

The WHO said Argentinian manufacturer Sinergium Biotech would lead the effort and had already begun developing candidate H5N1 vaccines.

The bird flu H5N1 first emerged in 1996, but since 2020 an in outbreaks in birds has occurred in parallel with the virus increasingly jumping to mammals, including cattle in US farms and a few humans.

This has prompted fears the virus could spark a future pandemic.

Sinergium is aiming to establish proof-of-concept in for its , the WHO said.

Once the preclinical data is ready, the technology,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More

Share This Article